DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA355184
Title:
IGF-IR Signaling in Breast Cancer.
Descriptive Note:
Annual rept. 15 Aug 97-14 Aug 98
Corporate Author:
THOMAS JEFFERSON UNIV PHILADELPHIA PA
Report Date:
1998-09-01
Pagination or Media Count:
68.0
Abstract:
Clinical and experimental evidence suggest that the insulin-like growth factor receptor IGF-IR is involved in breast cancer etiology. For instance, IGF-IR is overexpressed in breast tumors relative to normal breast epithelium and high levels of IGF-I an IGF-IR ligand correlate with breast cancer risk in premenopausal women. In vitro, IGF-IR regulates the growth and survival of breast cancer cells and plays a role in the development of estrogen-independence. Antiestrogens inhibit IGF-I- dependent growth by interfering with IGF-IR signaling. The mechanisms of this interference are not clear. Here we discuss the evidence that a pure antiestrogen ICI 182,780 specifically blocks breast cancer growth through downregulation of the expression of IRS-i, a major IGF signaling intermediate, Although the role of IGF-IR is breast cancer cell proliferation is clear, its function in growth-unrelated processes, such as cell adhesion, migration and metastasis is less well understood. Here, we report that an IGF-IR signaling substrate SHC, through its dynamic interactions with alpha5beta1integrin a fibronectin receptor participates in the regulation of breast cancer cell adhesion and motility.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
